ADVERTISEMENT
“Liraglutide has a proven efficacy in improving glycemic control in patients with type 2 diabetes mellitus. Clinical trials on Indian adult patients with type 2 diabetes mellitus over a 24‐week period have demonstrated Lirafit to be effective, safe and well‐tolerated,” the company says.
According to the ICMR‐INDIAB study carried out from October 2008 and December 2020, diabetes was found to have an overall weighted prevalence of 11.4% in India.
According to IQVIA sales data covering the 12 months leading up to August 2023 (MAT August 2023), the market size for GLP‐1 RA in India is estimated to be ₹259 crore, with an annual growth rate of 108% against the corresponding period last year (MAT August 2022).
The American Diabetes Association (ADA) also recommends GLP‐1 RAs therapy for weight loss and lesser risk of hypoglycemia in type 2 diabetes mellitus patients, the filing states.
August 2025
As India continues to be the world’s fastest-growing major economy, Fortune India presents its special issue on the nation’s Top 100 Billionaires. Curated in partnership with Waterfield Advisors, this year’s list reflects a slight decline in the number of dollar billionaires—from 185 to 182—even as the entry threshold for the Top 100 rose to ₹24,283 crore, up from ₹22,739 crore last year. From stalwarts like Mukesh Ambani, Gautam Adani, and the Mistry family, who continue to lead the list, to major gainers such as Sunil Mittal and Kumar Mangalam Birla, the issue goes beyond the numbers to explore the resilience, ambition, and strategic foresight that define India’s wealth creators. Read their compelling stories in the latest issue of Fortune India. On stands now.
“GLP‐1 RAs are recommended in the treatment guidelines by the American Diabetes Association as well as the American Association of Clinical Endocrinology (AACE) Consensus Statement & European Society of Cardiology for type 2 diabetes mellitus patients with co‐morbidities, like established atherosclerotic cardiovascular disease and obesity.” it adds.
Alok Malik, President and Business Head ‐ India Formulations, Glenmark Pharmaceuticals Ltd says Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus.
Fortune India is now on WhatsApp! Get the latest updates from the world of business and economy delivered straight to your phone. Subscribe now.